8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Mar 6, 2026·SEC
Sotera Health Company(SHC)Earnings, Financials & Key Ratios
SHC•NASDAQ
$18.02
66.7× P/E·Price updated Jul 7, 2026
AboutSotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.Show more
- Revenue$1.16B+5.7%
- EBITDA$303M-34.3%
- Net Income$78M+75.6%
- EPS (Diluted)0.27+68.8%
- Gross Margin55.48%+1.4%
- EBITDA Margin26.06%-37.8%
- Operating Margin33.75%+24.8%
- Net Margin6.7%+66.0%
- ROE15.42%+47.4%
SHC Price & Volume
Sotera Health Company (SHC) stock price & volume — 10-year historical chart
Loading chart...
Regulatory Headwinds Challenge Sotera Health's Profitability
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Strained
Cash Flow:Mixed
Primary Risk:Regulatory and litigation overhang
Key Thesis Takeaways
- Sotera Health operates as a critical, non-discretionary service provider in the medical sterilization supply chain, yet its fundamental outlook is clouded by significant litigation-related accruals and high financial leverage.
- While the company maintains gross margins consistently above 50%, the persistent threat of tightening EPA emission standards necessitates elevated capital expenditures that may continue to compress free cash flow.
- Investors should monitor the company's ability to manage its $2.3 billion debt load against the backdrop of volatile quarterly earnings and negative retained earnings of $505.5 million.
Verdict Logic
while the company maintains structural pricing power with gross margins above 50%, the high debt-to-equity ratio of 3.65 and ongoing regulatory risks warrant a cautious, wait-and-see approach.
SHC Growth Metrics
Sotera Health Company (SHC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years7.3%
3 Years5.05%
TTM7.44%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM374.7%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM369.39%
Return on Capital
10 Years9.08%
5 Years10.8%
3 Years11.4%
Last Year13.33%
SHC Recent Earnings
Sotera Health Company (SHC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.18+5.9%
$0.17
Rev
$280M+3.4%
$271M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.26+8.3%
$0.24
Rev
$303M+1.3%
$299M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.26+18.2%
$0.22
Rev
$311M+3.9%
$300M
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.20+17.6%
$0.17
Rev
$294M-3.5%
$305M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.18vs $0.17+5.9% | $280Mvs $271M+3.4% |
| Q1 2026 | Feb 24, 2026 | $0.26vs $0.24+8.3% | $303Mvs $299M+1.3% |
| Q4 2025 | Nov 4, 2025 | $0.26vs $0.22+18.2% | $311Mvs $300M+3.9% |
| Q3 2025 | Aug 8, 2025 | $0.20vs $0.17+17.6% | $294Mvs $305M-3.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Sotera Health Company (SHC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.02 | $5.14B | 66.74 | 5.74% | 6.7% | 15.42% | — | |
| $776.55 | $23.83B | 82.79 | 17.69% | 12.02% | 32.26% | — | |
| $168.72 | $12.92B | 58.18 | -0.37% | 5.35% | 4.7% | — | |
| $228.68 | $11.01B | -78.58 | -0.85% | -4.59% | -5.66% | — | |
| $546.29 | $15.6B | 35.75 | 19.97% | 17.19% | 120.89% | — | |
| $28.26 | $2.34B | 128.45 | -10.86% | -2.42% | -1.59% | — |
Compare SHC vs Peers
Sotera Health Company (SHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SHC SEC Filings & Documents
Sotera Health Company (SHC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SHC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SHC Frequently Asked Questions
Sotera Health Company (SHC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Sotera Health Company's revenue?
Sotera Health Company (SHC) reported $1.19B in revenue for fiscal year 2025. This represents a 59% increase from $746.1M in 2018.
How fast is Sotera Health Company growing?
Sotera Health Company (SHC) grew revenue by 5.7% over the past year. This is steady growth.
Is SHC profitable?
Yes, Sotera Health Company (SHC) is profitable, generating $117.8M in net income for fiscal year 2025 (6.7% net margin).
Dividend & Returns
What is SHC's return on equity?
Sotera Health Company (SHC) has a return on equity (ROE) of 15.4%. This is reasonable for most industries.
What is Sotera Health Company's free cash flow?
Sotera Health Company (SHC) generated $111.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.